Shares of CureVac were up roughly 40 percent Monday following its CEO Franz-Werner Haas stated in a meeting with the German financial news website Boerse Online on the weekend he was optimistic its vaccine will probably be accepted by regulators early annually. Haas added an"accelerated approval was potential" too.
CureVac recently obtained approval from the authorities of Germany and Belgium to begin clinical trials for a few of its own vaccines for Covid-19.
Hopp possesses almost half CureVac. The German authorities and Big Pharma chief GlaxoSmithKline (GSK)als) have large stakes in the business.
Musk tweeted that Tesla's German Grohmann department is helping assemble receptor printers for CureVac -- a"side project" which Tesla could expand to include additional drug firms.